Leerink notes that CMS released a set of preliminary determinations for the clinical lab fee schedule, including having crosswalked Quanterix’s (QTRX) LucentAD Complete test to a $897 price. While coverage of blood biomarkers remains limited, the firm calls the pricing on CLFS a “meaningful positive” for Quanterix and believes average selling prices could see further upside if the company obtains ADLT status. The firm has a Market Perform rating on Quanterix shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX:
- Quanterix Earnings Call: Strategic Gains Amid Financial Hurdles
- Quanterix downgraded to Hold from Buy at Canaccord
- Quanterix’s Strategic Acquisition and Growth Potential Amidst Challenges
- Quanterix Reports Q2 2025 Financial Results
- Quanterix Hold Rating: Balancing Underperformance with Strategic Opportunities